Abstract
Why differentiate low molecular weight heparins for venous thromboembolism?
Highlights
The low molecular weight heparins (LMWHs) represent a group of antithrombotic and anticoagulant drugs which were initially developed for the prophylaxis of surgical thrombosis some 20 years ago
It is clear that the clinical spectrum of the LMWHs is relatively broader from the different anticoagulant/antithrombotic drugs
It is important to differentiate the therapeutic effects of individual LMWH as each of these products is approved for specific indications
Summary
The low molecular weight heparins (LMWHs) represent a group of antithrombotic and anticoagulant drugs which were initially developed for the prophylaxis of surgical thrombosis some 20 years ago. 2. Differentiation of commercially available low molecular weight heparins, which are produced by different methods. 3. Differentiation of the branded low molecular weight heparins from the generic versions of these drugs.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
